Abstract:BackgroundTransarterial chemoembolisation (TACE) is still widely used to treat patients with advanced hepatocellular carcinoma who have no access to sorafenib in Asia. However, the indication of TACE for these patients has yet to be established. We established an objective point score to guide this decision in patients with advanced-stage hepatocellular carcinoma.MethodsWe developed a scoring system (MCCT score) based on preoperative data from a cohort of 422 patients receiving TACE as the first treatment for advanced hepatocellular carcinoma from 2006 to 2013 at Sun Yat-sen University Cancer Center, Guangzhou, China. Factors determining survival were analysed by univariate and multivariate analysis and Cox proportional hazard regression models. The scoring system was retrospectively validated in an external cohort from other two institutions (Dongguan People's Hospital and the Kaiping Central Hospital; n=237). The prognostic predictive power was compared with six different staging systems: tumour node metastasis (TNM), 7th edition; Cancer of the Liver Italian Program (CLIP); Chinese University Prognostic Index (CUPI); Okuda, Japan Integrated Staging (JIS); and Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire (GRETCH). The retrospective study was approved by the institutional review board; written informed consent was obtained from each patient.FindingsThe presence of macroscopic vascular invasion (M), Child-Pugh class B (C), C-reactive protein values (C) higher than 10 mg/L, and tumour size (T) larger than 7 cm were independent negative prognostic factors for survival and were used to create the MCCT score. The patients were divided into risk groups on the basis of their MCCT scores (low risk for ≤2 points, intermediate risk for 3–4 points, and high risk for five points). The median overall survival times were 14·4 months (95% CI 10·7–18·1) for the low-risk group, 6·8 months (6·0–7·6) of the intermediate-risk group, and 3·2 months (1·7–4·7) for the high-risk group (p<0·0001). The discriminative ability, as determined by the area under the curve (AUC) at 6 and 12 months (AUCs 0·692 at 6 months and 0·702 at 12 months) seemed to be greater than the ability of the six other hepatocellular carcinoma staging systems (AUCs range 0·501 to 0·633). The findings were supported by the external validation cohort.InterpretationThe MCCT scoring system is more accurate than the six other scoring systems in selecting patients with advanced hepatocellular carcinoma for TACE. For patients with advanced hepatocellular carcinoma with no access to sorafenib, TACE may be a valuable alternative in selecting patients (MCCT score ≤2).FundingThis study was supported by grants from the National Natural Science Foundation of China (81172037/H1606, 81272639, and 81572385), Guangdong province science and technology project of China (2013B021800159), and the Fundamental Research Funds for the Central Universities of China (13ykzd24).

Risk prediction for patients with hepatocellular carcinoma undergoing chemoembolization: development of a prediction model

A refined prediction model for survival in hepatocellular carcinoma patients treated with transarterial chemoembolization

Development and Validation of a Risk Prediction Algorithm for Evaluating the Efficacy of Postoperative Adjuvant TACE Therapy for Hepatocellular Carcinoma

Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based Approach

Development and validation of survival prediction models for patients with hepatocellular carcinoma treated with transcatheter arterial chemoembolization plus tyrosine kinase inhibitors

Novel Prognostic Nomogram to Predict Progression-Free Survival of Patients with Hepatocellular Carcinoma After Transarterial Chemoembolization

Prediction Model of No-Response Before the First Transarterial Chemoembolization for Hepatocellular Carcinoma: TACF Score

A New Prediction Model for Prognosis of Patients with Intermediate HCC after Conventional Transarterial Chemoembolization.

Development and Validation of a Predictive Model for Early Refractoriness of Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma

A Novel Risk Prediction Model for Patients with Combined Hepatocellular-Cholangiocarcinoma.

Development and Validation of a Prognostic Model for Transarterial Chemoembolization in Unresectable Hepatocellular Carcinoma Based on Preoperative Serum Prealbumin

ASARA, a prediction model based on Child-Pugh class in hepatocellular carcinoma patients undergoing transarterial chemoembolization

A New Prediction Model for Prognosis of Patients with Intermediate-Stage HCC after Conventional Transarterial Chemoembolization: an Internally Validated Study.

Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: a multicentre observational study.

A Novel Pre-treatment Model Predicting Risk of Developing Refractoriness to Transarterial Chemoembolization in Unresectable Hepatocellular Carcinoma.

Development of a Prognostic Score for Recommended TACE Candidates with Hepatocellular Carcinoma Spontaneous Rupture

Development and Validation of a Prediction Model for Hepatitis B Virus-Related Hepatocellular Carcinoma Patients Receiving Postoperative Adjuvant Transarterial Chemoembolization

A Novel Risk Score (MCCT) to Guide Decision for Treatment of Advanced Hepatocellular Carcinoma with Transarterial Chemoembolisation: a Derivation and Validation Study

A simplified model for prophylactic transarterial chemoembolization after resection for patients with hepatocellular carcinoma

Development of a Prognostic Score for Recommended Transarterial Chemoembolization Candidates with Spontaneous Rupture of Hepatocellular Carcinoma.

A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer